AstraZeneca Annual Report and Form 20-F 2002 Operational Review www.
com 22 Development Pipeline Phase Estimated filing date Compound Mechanism Areas under investigation PC 1 2 3 MAA NDA Gastrointestinal GI NCEs AZD0865 reversible acid pump inhibitor acid related GI disease 2005 2005 AZD3355  2005 2005 sphincter relaxations AZD9343 inhibitor of transient lower oesophageal GERD 2005 2005 sphincter relaxations Line extensions Nexium proton pump inhibitor NSAID GI side effects symptom resolution 2Q 2003 2Q 2003 parenteral formulation 2Q 2003 2Q 2003 NSAID GI side effects healing and prevention 1H 2004 1H 2004 extra-oesophageal reflux disease 2005 2005 Cardiovascular CV NCEs Crestor statin dyslipidaemia Filed Filed Crestor statin atheroma 2005 2005 Crestor statin outcomes 2005 2005 Exanta melagatran thrombin inhibitor sc prevention of VTE Filed 2005 Exanta H376 95 thrombin inhibitor prevention of VTE Filed 4Q 2003 prevention of stroke in AF 4Q 2003 4Q 2003 treatment of VTE 4Q 2003 2005 arterial post MI 2005 2005 Galida PPAR agonist diabetes metabolic syndrome 2005 2005 AZD6140 ADP antagonist arterial thrombosis 2005 2005 AZD7009 atrial repolarisation delaying agent ARDA AF 2005 2005 AZD9684 CPU inhibitor thrombosis 2005 2005 AZD0837 thrombin inhibitor thrombosis 2005 2005 AZD7806 IBAT inhibitor dyslipidaemia 2005 2005 Line extensions Atacand angiotensin II antagonist hypertension outcomes SCOPE study Filed Under evaluation CHF outcomes CHARM study 4Q 2003 4Q 2003 diabetic retinopathy 2005 2005 Toprol-XL beta blocker HCTZ combination 2005 submission for variation to existing label.
Oncology NCEs Faslodex oestrogen receptor antagonist 2nd line advanced breast cancer 1Q 2003 Launched 1st line advanced breast cancer 2005 2005 Iressa EGFR-TK inhibitor NSCLC 1Q 2003 Filed ZD6474 angiogenesis inhibitor VEGFR-TKI solid tumours 2005 2005 ZD4054 endothelin A receptor antagonist solid tumours 2005 2005 ZD6126 vascular targeting agent solid tumours 2005 2005 AZD2171 angiogenesis inhibitor VEGFR-TKI solid tumours and haematological malignancies 2005 2005 AZD3409 farnesyl-transferase inhibitor solid tumours 2005 2005 AZD0530 non-receptor tyrosine kinase inhibitor solid tumours 2005 2005 AZD4440 vascular targeting agent solid tumours 2005 2005 AZD9935 angiogenesis inhibitor VEGFR-TKI solid tumours 2005 2005 Line extensions Arimidex aromatase inhibitor adjuvant breast cancer Launched Launched Casodex anti-androgen early prostate cancer Launched Under evaluation Zoladex LHRH agonist pre-menopausal adjuvant breast cancer Launched Iressa EGFR-TK inhibitor head and neck cancer 2005 2005 breast cancer 2005 2005 colorectal cancer 2005 2005 AstraZeneca Annual Report and Form 20-F 2002 Operational Review www.
com 23 Phase Estimated filing date Compound Mechanism Areas under investigation PC 1 2 3 MAA NDA Respiratory and Inflammation NCEs AZD9056 ion channel blocker rheumatoid arthritis 2005 2005 AZD8309 chemokine receptor antagonist rheumatoid arthritis 2005 2005 AZD7140 chemokine receptor antagonist rheumatoid arthritis 2005 2005 AZD3342 protease inhibitor COPD 2005 2005 AZD0275 chemokine receptor antagonist COPD 2005 2005 AZD0902 ion channel blocker COPD 2005 2005 AZD8955 collagenase inhibitor osteoarthritis 2005 2005 First indication: use in other diseases such as COPD under consideration.
Line extensions Symbicort inhaled steroid fast onset, COPD Filed Turbuhaler long-acting betaagonist 2 single therapy for asthma 3Q 2003 Symbicort pMDI inhaled steroid fast onset, asthma 4Q 2003 1H 2004 long-acting betaagonist 2 Oxis Turbuhaler fast onset, long-acting betaagonist COPD Approved 2 Oxis pMDI fast onset, long-acting betaagonist asthma 3Q 2003 2 Central Nervous System CNS NCEs Cerovive free radical trapping agent stroke 2005 2005 ZD0947 K channel opener overactive bladder 2005 2005 AR-A2 5HT antagonist anxiety depression 2005 2005 1B AZD1134 5HT antagonist anxiety depression 2005 2005 1B AZD5106 NK-2 antagonist overactive bladder 2005 2005 AZD4750 chemokine receptor antagonist multiple sclerosis 2005 2005 AZD0328 alpha-7 nicotinic Alzheimers disease 2005 2005 receptor agonist Line extensions Seroquel D2 5HT2 antagonist granules 2005 2005 sustainedrelease Under Under evaluation evaluation mania 1Q 2003 Filed Zomig 5HT1B 1D receptor antagonist nasal spray Launched Filed Pain Control NCEs AZD3582 CINOD acute chronic nociceptive pain 2005 2005 AZD4282 NMDA antagonist neuropathic pain 2005 2005 AZD4717 CINOD acute chronic nociceptive pain 2005 2005 Line extensions Naropin sodium channel blocker spinal anaesthesia Filed Infection Line extensions Merrem carbapenem antibiotic skin and soft tissue infections 4Q 2003 ADP adenoside diphosphate IBAT ilial bile acid transport NSCLC non-small cell lung cancer AF atrial fibrillation K potassium PC pre-clinical: candidate drug accepted for CHF congestive heart failure LHRH luteinisinghormone releasing hormone development but not yet administered to man CINOD Cox inhibiting nitric oxide donator MAA marketing authorisation application Europe pMDI pressurised metered dose inhaler COPD chronic obstructive pulmonary disease MI myocardial infarction PPAR peroxisome  receptor CPU carboxy peptidase-U NCE new chemical entity sc subcutaneous EGFR-TKI epidermal growth factor NDA new drug application US VEGFR-TKI vascular endothelial cell growth factor receptor-tyrosine kinase inhibitor NK-2 neurokinin 2 antagonist receptor-tyrosine kinase inhibitor GERD gastro-oesophageal reflux disease NMDA N-methyl-D-aspartate VTE venous thromboembolism HCTZ hydrochlorothiazide NSAID non-steroidal anti-inflammatory drug 2005 not earlier than 2006
